Madrigal Pharma (NASDAQ: MDGL) reported Q4 EPS of ($2.71), $1.77 better than the analyst estimate of ($4.48). Revenue for the quarter came in at $103.32 million versus the consensus estimate of $87.7 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.